The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

PHASE4RecruitingINTERVENTIONAL

Enrollment

1,800

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2028

Conditions

Atrial Fibrillation Patients With Intermediate Stroke Risk

Interventions

DRUG

Anticoagulation group(Apixaban group)

Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years

Trial Locations (1)

RECRUITING

Severance Cardiovascular Hospital Yonsei University, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER